Navigation Links
International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury
Date:5/31/2009

Chicago (June 1, 2009) The International Serious Adverse Events Consortium (SAEC) announced today initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI). The SAEC is a nonprofit research corporation, launched in the fall of 2007, comprised of and funded by 10 leading pharmaceutical companies and the Wellcome Trust. The U.S. Food and Drug Administration (FDA) also contributes to the scientific and strategic direction of this novel research effort. The collection and initial characterization of the DILI cases supporting these results was performed by the UK-based DILIGEN network, led by Professor Ann Daly and colleagues at Newcastle University, but also involving researchers at the University of Liverpool and at Queen's Medical Centre, Nottingham.

Patients respond differently to medicines, and all medicines can have adverse effects in some people. The SAEC's work is based on the hypothesis that many of these differences have a genetic basis. Its research studies are exploring the impact genetics can have on how individuals respond to medicines. There are a large number of drugs that can cause liver injury in a very small subset of patients, and in rare cases this may lead to acute liver failure. Although the exact mechanisms behind such rare and unpredictable DILI is unknown, research suggests a genetic contribution.

In a Nature Genetics paper published on May 31, the SAEC and Newcastle University's analysis of a subset of DNA patients has led to the discovery that HLA-B*5701 is a major determinant of liver injury induced by flucloxacillin. Flucloxacillin is an antibiotic widely used in Europe and Australia, mainly in the treatment of staphylococcal infections. HLA-B is one of a number of highly variable genes responsible for immune function. The study found that individuals carrying at least one copy of HLA-B*5701 were 80-100 times more likely than non-carriers to develop DILI in response to this antibiotic. This risk-associated variant is relatively common in Europe, but less prevalent in Africa and East Asia. In addition to HLA-B*5701, variations on chromosome 3 were also found to influence the risk for DILI. These findings provide initial insights into the mechanism of DILI and may have the potential to help identify individuals who have an increased risk for flucloxacillin related liver injury. Despite being at substantially higher risk than non-carriers, only a small proportion of carriers actually develop liver problems in response to flucloxacillin. Thus, further analysis and research will be needed to determine whether a clinically useful biomarker test could be developed for this susceptibility.

The paper can be found on both the Nature Genetics (http://www.nature.com/ng/index.htm) and the SAEC's (www.saeconsortium.org) websites. Qualified researchers, who enter into a data use agreement, can obtain free access via the SAEC's website to the supporting study data, for use exclusively in biomedical research.

"We are pleased to be able to provide these initial results to the research community, to both improve the productivity of drug development and to begin the critical process of developing validated biomarkers to forecast patients who may be at risk for DILI," said Arthur Holden, founder and chairman of the SAEC. "To date, in conjunction with our collaborators, we have assembled one of the largest DILI research collections in the world. We expect additional important DILI genetic findings to emerge from these research efforts over the next 12-18 months."

"Our aim is to ensure that commonly prescribed drugs can be used more safely. This is an important step in developing a test that can be used prior to prescribing flucloxacillin. We look forward to making further progress in the area of DILI research with our international collaborators" said Ann Daly, Professor of Pharmacogenetics at Newcastle University who leads the DILIGEN network.


'/>"/>

Contact: Arthur Holden
aholden@earthlink.net
773-867-8595
International Serious Adverse Events Consortium
Source:Eurekalert

Related biology news :

1. World-class innovation through international cooperation
2. International team tracks clues to HIV
3. SRI International to screen drugs that fight 2009 H1N1 influenza A
4. SRI International receives $100,000 Grand Challenges Explorations grant
5. International team finds key gene that allows plants to survive drought
6. BIO-key(R) International Showcasing Biometric Identification Technology at 2009 RSA Conference
7. Canadian biomedical engineering pioneer receives international award
8. Major international study challenges notions of how genes are controlled in mammals
9. International honor for University of East Anglia ocean researcher
10. Biomedical researchers invited to design experiments for the International Space Station
11. International climate change researchers meet, review latest findings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... of multiple immunoassay-based threat detection technologies by researchers from the Pacific National ... threat detection technology was found to have the best level of detection ...
Breaking Biology Technology: